BioAge Reports Q2 2026 Results, Doses First Participant in BGE-102 Phase 2 Trial
BioAge Labs dosed the first participant in its Phase 2 trial of BGE-102 and plans to initiate a proof-of-concept trial for diabetic macular edema, signaling progress in its NLRP3 inhibition strategy.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day